Literature DB >> 2738154

Fibrinogen Stony Brook, a heterozygous A alpha 16Arg----Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly.

D K Galanakis1, A Henschen, E I Peerschke, M Kehl.   

Abstract

Assessed by high performance liquid chromatographic and amino acid sequence determinations, approximately one half (n = 4) of A peptide in fibrinogen Stony Brook (phi SB) contained the A alpha 16Arg----Cys substitution. To examine its functional behavior, mutant molecule-rich soluble subfractions that partly or fully lacked their normal A peptide were obtained from cryoprecipitates or from incoagulable material, respectively. Such subfractions consistently induced a more pronounced decrease (n = 3) in the turbidity of normal polymerizing fibrin than that induced by normal fibrinogen, by whole phi SB (n = 4) or by fibrinogen from an unrelated homozygous proband. These subfractions also exhibited decreased (12-50% of normal controls, fibrinogen 30-590 nM, n = 5) ADP-induced aggregation support of gel-sieved platelets, a decrease not demonstrable by whole phi SB, by fibrinogen from the homozygous proband, or by enrichment of the latter with normal soluble fibrin. A single isolate displaying diminished platelet aggregation support was 125I-labeled and examined further. It exhibited decreased binding to platelets, and Scatchard analysis indicated decreased binding affinity but normal maximum binding. We infer that phi SB contained heterodimers that exhibited these distinct functional properties when their normal A peptide had been cleaved.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2738154      PMCID: PMC303982          DOI: 10.1172/JCI114154

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Cigarette smoke contains anticoagulants against fibrin aggregation and factor XIIIa in plasma.

Authors:  D K Galanakis; P Laurent; A Janoff
Journal:  Science       Date:  1982-08-13       Impact factor: 47.728

Review 2.  Surface markers of fibrinogen and its physiologic derivatives revealed by antibody probes.

Authors:  E F Plow; T S Edgington
Journal:  Semin Thromb Hemost       Date:  1982-01       Impact factor: 4.180

Review 3.  Fibrinogen and fibrin.

Authors:  R F Doolittle
Journal:  Annu Rev Biochem       Date:  1984       Impact factor: 23.643

4.  Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen gamma chain.

Authors:  M Kloczewiak; S Timmons; J Hawiger
Journal:  Biochem Biophys Res Commun       Date:  1982-07-16       Impact factor: 3.575

5.  Evidence for interaction between platelet fibrinogen receptors.

Authors:  E I Peerschke
Journal:  Blood       Date:  1982-10       Impact factor: 22.113

6.  Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-A alpha 16 by a histidyl residue. Evidence for thrombin-catalyzed hydrolysis at a histidyl residue.

Authors:  D L Higgins; J A Shafer
Journal:  J Biol Chem       Date:  1981-12-10       Impact factor: 5.157

7.  Carboxy-terminal amino acid sequence of a human fibrinogen gamma-chain variant (gamma').

Authors:  C Wolfenstein-Todel; M W Mosesson
Journal:  Biochemistry       Date:  1981-10-13       Impact factor: 3.162

8.  Analysis of human fibrinopeptides by high-performance liquid chromatography.

Authors:  M Kehl; F Lottspeich; A Henschen
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1981-12

9.  Binding of fibrinogen to ADP-treated platelets. Comparison of plasma fibrinogen fractions and early plasmic fibrinogen derivatives.

Authors:  E I Peerschke; D K Galanakis
Journal:  J Lab Clin Med       Date:  1983-03

10.  Novel structure elucidation strategy for genetically abnormal fibrinogens with incomplete fibrinopeptide release as applied to fibrinogen Schwarzach.

Authors:  A Henschen; M Kehl; E Deutsch
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1983-12
View more
  10 in total

Review 1.  Mechanisms of fibrin polymerization and clinical implications.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

2.  Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots.

Authors:  J P Collet; J L Woodhead; J Soria; C Soria; M Mirshahi; J P Caen; J W Weisel
Journal:  Biophys J       Date:  1996-01       Impact factor: 4.033

Review 3.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

4.  Abnormal fibrinogens IJmuiden (B beta Arg14----Cys) and Nijmegen (B beta Arg44----Cys) form disulfide-linked fibrinogen-albumin complexes.

Authors:  J Koopman; F Haverkate; J Grimbergen; L Engesser; I Nováková; A F Kerst; S T Lord
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

5.  Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).

Authors:  A M Aly; M Arai; L W Hoyer
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

6.  Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense.

Authors:  Joni M Prasad; Oleg V Gorkun; Harini Raghu; Sherry Thornton; Eric S Mullins; Joseph S Palumbo; Ya-Ping Ko; Magnus Höök; Tovo David; Shaun R Coughlin; Jay L Degen; Matthew J Flick
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

Review 7.  Abnormal fibrinogen with an Aα 16Arg → Cys substitution is associated with multiple cerebral infarctions.

Authors:  Meiling Luo; Aiqiu Wei; Liqun Xiang; Jie Yan; Lin Liao; Xuelian Deng; Donghong Deng; Peng Cheng; Faquan Lin
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

Review 8.  Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders.

Authors:  Giovanni Luca Tiscia; Maurizio Margaglione
Journal:  Int J Mol Sci       Date:  2018-05-29       Impact factor: 5.923

9.  A Chinese family with congenital Dysfibrinogenemia carries a heterozygous missense mutation in FGA: Concerning the genetic abnormality and clinical treatment.

Authors:  Jihao Zhou; Peng Zhu; Xinyou Zhang
Journal:  Pak J Med Sci       Date:  2017 Jul-Aug       Impact factor: 1.088

10.  Identification and characterization of novel mutations implicated in congenital fibrinogen disorders.

Authors:  Natalie Smith; Larissa Bornikova; Leila Noetzli; Hugo Guglielmone; Salvador Minoldo; Donald S Backos; Linda Jacobson; Courtney D Thornburg; Miguel Escobar; Tara C White-Adams; Alisa S Wolberg; Marilyn Manco-Johnson; Jorge Di Paola
Journal:  Res Pract Thromb Haemost       Date:  2018-07-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.